Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information

International Journal of Cancer

Volumn 136, Issue 4, 2015, Pages 863-874

  Jayawardana, Kaushala ^a   Schramm, Sarah Jane ^b,c   Haydu, Lauren ^c   Thompson, John F ^a,c   Scolyer, Richard A ^a,c,d   Mann, Graham J ^b,c   Müller, Samuel ^a   Yang, Jean Yee Hwa ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Biomarkers; Data integration; Melanoma; Prevalidation; Prognosis

Indexed keywords

MESSENGER RNA; MICRORNA; PROTEOME; TUMOR MARKER;

ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; INFORMATION SYSTEM; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; ONCOGENE; ONCOGENE N RAS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROTEIN EXPRESSION; SOMATIC MUTATION; VALIDATION PROCESS; GENETICS; MELANOMA; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; SECONDARY; SKIN TUMOR;

COHORT STUDIES; DNA MUTATIONAL ANALYSIS; HUMANS; MELANOMA; MICRORNAS; PROGNOSIS; PROTEOME; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84918777103     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29047     Document Type: Article

References (43)

1. Slipicevic A, Herlyn M. Narrowing the knowledge gaps for melanoma. Upsala J Med Sci 2012;117: 237-43
2. Lucas R, McMichael T, Smith W, et al. Solar ultraviolet radiation. Global burden of disease from solar ultraviolet radiation. World Health Organization Public Health and the Environment, Geneva, 2006
3. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009;27:3-9
4. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2009 (Vintage 2009 populations). National Cancer Institute, Bethesda, MD, 2012
5. Marrett LD, Nguyen HL, Armstrong BK. Trends in the incidence of cutaneous malignant melanoma in New South Wales, 1983-1996. Int J Cancer 2001;92:457-62
6. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687-701
7. de Vries E, Willem Coebergh J. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004;40: 2355-66
8. Guy GPJ, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and nonmelanoma skin cancer: A systematic review of the literature. PharmacoEconomics 2011;29:863-74
9. Gershenwald J, Soong S-J, Balch C, Committee ObotAJCoCMS. 2010 TNM staging system for cutaneous melanoma. . .and beyond. Ann Surg Oncol 2010;17:1475-7
10. Murali R, Hughes MT, Fitzgerald P, et al. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly clark level, affects pathologic staging of primary cutaneous melanoma. Ann Surg 2009; 249:641-7
11. Balch CM, Gershenwald JE, Soong SJ, et al. Final Version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 2009;27: 6199-206
12. Murali R, Thompson JF, Scolyer RA. Sentinel lymph node biopsy for melanoma: Aspects of pathologic assessment. Future Oncol 2008;4:535-51
13. Weigelt B, Baehner FL, Reis JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: A retro- spective of the last decade. J Pathol 2010;220: 263-80
14. Timar J, Gyorffy B, Raso E. Gene signature of the metastatic potential of cutaneous melanoma: Too much for too little? Clin Exp Metastat 2010;27: 371-87
15. Schramm S-J, Campain AE, Scolyer RA, et al. Review and cross-validation of gene expression signatures and melanoma prognosis. J Invest Dermatol 2012;132:274-83
16. Segura MF, Greenwald HS, Hanniford D, et al. MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis 2012;33:1823-32
17. Tremante E, Ginebri A, Lo Monaco E, et al. Melanoma molecular classes and prognosis in the postgenomic era. Lancet Oncol 2012;13:e205-e11
18. John T, Black MA, Toro TT, et al. Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 2008;14: 5173-80
19. Bogunovic D, O'Neilla DW, Belitskaya-Levya I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 2009;106:20429-34
20. Mandruzzato S, Callegaro A, Turcatel G, et al. A gene expression signature associated with survival in metastatic melanoma. J Transl Med 2006;4:1-11
21. Segura MF, Belitskaya-Levy I, Rose AE, et al. Melanoma microRNA signature predicts postrecurrence survival. Clin Cancer Res 2010;16: 1577-86
22. Jönsson G, Busch C, Knappskog S, et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 2010;16: 3356-67
23. Caramuta S, Egyhazi S, Rodolfo M, et al. Micro- RNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 2010;130:2062-70
24. Mann GJ, Pupo GM, Campain AE, et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 2013;133:509-17
25. Thomas RK, Baker AC, DeBiasi RM, Winckler W, LaFramboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill LE, Lee JC, Nicoletti R, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39:347-51
26. Mactier S, Kaufman KL, Wang P, Crossett B, Pupo GM, Kohnke PL, Thompson JF, Scolyer RA, Yang JY, Mann GJ, Christopherson RI. Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell Melanoma Res, in press
27. R Development Core Team. R: A language and environment for statistical computing. Austria: R Foundation for Statistical Computing Vienna, 2012
28. Campain A. Challenges associated with clinical studies and the integration of gene expression data. Ph.D. Sydney: Faculty of Science, School of Mathematics and Statistics, The University of Sydney, 2012
29. Tibshirani RJ, Efron B. Pre-validation and inference in microarrays. Stat Appl Genet Mol Biol 2002;1
30. Cortes C, Vapnik V. Support-vector networks. Mach Learn 1995 20: 273-97
31. Tibshirani R, Hastie T, Narasimhan B, et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci 2002;99: 6567-72
32. Schramm S-J, Menzies AM, Mann GJ. Molecular biomarkers of prognosis in melanoma: how far are we from the clinic? Melanoma Res 2013;23: 423-5
33. Griewank KG, Scolyer RA, Thompson JF, et al. Genetic alterations and personalized medicine in melanoma: Progress and future prospects. J Natl Cancer Inst 2014;106
34. Miller DM, Flaherty KT, Tsao H. Commentary: molecular testing in melanoma. J Am Acad Dermatol 70:863-70
35. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19: 3635-48
36. Davar D, Kirkwood JM. New therapies in the treatment of melanoma. Expert Opin Invest Drugs 2012;21:1643-59
37. Menzies AM. New systemic therapies for metastatic melanoma-mapk inhibitors and immunotherapy [online]. Cancer Forum 2012;36: 160-5
38. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: new insights and new therapies. J Invest Dermatol 2012;132:854-63
39. Gevaert O, Smet FD, Timmerman D, et al. Predicting the prognosis of breast cancer by integrating clinical and microarray data with Bayesian networks. Bioinformatics 2006;22:e184-e90
40. Daemen A, Gevaert O, Ojeda F, et al. A kernel-based integration of genome-wide data for clinical decision support. Genome Med 2009;1: 39.1-17
41. Bergersen LC, Glad IK, Lyng H. Weighted lasso with data integration. Stat Appl Genet Mol Biol 2011;10:1-41
42. Matheis KA, Com E, Gautier J-C, et al. Crossstudy and cross-omics comparisons of three nephrotoxic compounds reveal mechanistic insights and new candidate biomarkers. Toxicol Appl Pharmacol 2011;252:112-22
43. Scolyer RA, Thompson JF. Biospecimen banking: The pathway to personalized medicine for patients with cancer. J Surg Oncol 2012;107:681-2.